Market: NASD |
Currency: USD
Address: 535 W 24th Street
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
📈 Neurogene Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$47.40
-
Upside/Downside from Analyst Target:
136.76%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-15
-
EPS Estimate:
-1.09
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.250000 |
- |
2023-12-19 |
- |
Stock split |
| $0.200000 |
- |
2023-09-25 |
- |
Stock split |
|
Total Amount for 2023: $0.450000 |
📅 Earnings & EPS History for Neurogene Inc.
| Date | Reported EPS |
|---|
| 2025-11-14 (estimated upcoming) | - |
| 2025-08-11 | -1.05 |
| 2025-05-09 | -1.08 |
| 2025-03-24 | -0.99 |
| 2024-11-18 | -1.19 |
| 2024-08-09 | -1.09 |
| 2024-05-10 | -1 |
📰 Related News & Research
No related articles found for "neurogene inc".
